Preclinical feature articles

  1. The Clinical Landscape Of ADCs In 2023: Diverse Technologies, Narrow Target 3/16/2023

    Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the potency of cytotoxic drugs. This article shares data surrounding the ADCs currently entering clinical trials, a look at failed ADC programs, and more.

  2. Tackling Safety Issues Of Adjuvanted Vaccines 3/8/2023

    An adjuvant is a substance added to some vaccines to enhance the immune response and/or to reduce the number of doses required to achieve a protective effect. This article discusses the emerging use of adjuvants and assessing safety issues.

  3. Search For Similarity: Regulatory Considerations Of Drug Abuse Potential Investigations 10/14/2022

    This article focuses on FDA and EMA regulatory guidelines surrounding drug abuse/dependence and abuse potential investigations, particularly in animal studies. Discussion includes penetration of the blood-brain barrier, structural similarity screening, and investigation of pharmacological similarity.

  4. Is Phage Therapy Ushering In A Post-Antibiotic Era? 10/3/2022

    Faced with the emergence of resistant bacteria, phage therapy, which uses bacterial viruses (bacteriophages) to treat bacterial infections, is emerging as one of the most credible alternatives to antibiotics.

  5. A New Pain Treatment Requires Accurate And Reliable Data 9/21/2022

    South Rampart Pharma aims to deliver a new, affordable treatment for pain that will avoid the issues with currently marketed products. Opioids are highly addictive; patients taking excessive amounts of acetaminophen can develop liver toxicity; and NSAID over-exposure risks kidney toxicity, gastrointestinal (GI) bleeding, and worsening of high blood pressure in patients with hypertension.

  6. Collaborating With Academia For Drug Discovery Targeting Immune-Mediated Diseases 9/16/2022

    Last year, Janssen Biotech and the University of Oxford established a collaboration to understand pathogenic pathways driving immune-mediated inflammatory diseases. They have been creating a cellular map of expressed genes and proteins. This article shares what the collaboration has accomplished so far.

  7. Beyond Nuclear Genetics: Let's Think Differently About CNS Disease Targets 9/12/2022

    Nuclear genes with mutations remain the primary focus for selecting biological drug targets, but we have yet to see a drug come to market from a genetically validated target that can arrest or reverse diseases like Parkinson’s. We need to expand our research to explore the essential drivers, genetic or otherwise, that switch our cells from order to disorder or from function to dysfunction.

  8. Your 3-Step Process For Innovation In Precision Medicine 8/3/2022

    Scientific advances are exciting, but not every discovery translates well into the clinic. Why is that? And how can companies successfully position themselves for market success with their drug discovery efforts? 

  9. Uncovering Rare Pediatric Diseases Through Atypical Gene Associations 5/12/2022

    A conversation with Carol Saunders, PhD, FACMG, FABMGG, and Isabelle Thiffault, PhD, FABMGG, illuminates the genome sequencing research work they are doing at the Clinical Genetics and Genomics Laboratory at Children's Mercy Kansas City and the Genomic Medical Center at Children's Mercy Research Institute.

  10. Shining Light on the Commercial Potential of Optogenetic Therapies 2/3/2022

    Light can be used to stimulate light-sensitive receptors in order to turn brain cells “on” and “off” at the flip of a switch, called optogenetics. Until recently, its use has been restricted to use in preclinical animal models, but now, advances have allowed this technology to move from the lab to humans. This article shares recent advances in optogenetics, the landscape of optogenetic therapies currently in clinical trials, and more.